Table 2.
Patients reporting ≥1 antibiotic by class and mean duration of antibiotic use, among antibiotic users by patient status and country
| Outpatient | Inpatient | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Argentina N = 75 | Hungary N = 75 | Mexico N = 75 | Peru N = 101 | Poland N = 75 | Total N = 401 | Argentina N = 75 | Hungary N = 81 | Mexico N = 77 | Peru N = 78 | Poland N = 75 | Total N = 386 | |
| Patients prescribed ≥1 antibiotic, n (%) | 17 (22.7) | 2 (2.7) | 6 (8.0) | 17 (16.8) | 9 (12.0) | 51 (12.7) | 54 (72.0) | 45 (55.6) | 57 (74.0) | 67 (85.9) | 43 (57.3) | 266 (68.9) |
| Mean (95% CI), number of antibiotics prescribed per patient a | 1.8 (1.2, 2.5) | 1.0 (0.2, 3.1) | 1.5 (0.7, 2.7) | 1.1 (0.7, 1.7) | 1.1 (0.6, 1.9) | 1.4 (1.1, 1.7) | 2.1 (1.7, 2.5) | 1.7 (1.4, 2.1) | 2.5 (2.1, 2.9) | 2.2 (1.8, 2.5) | 1.5 (1.2, 1.9) | 2.0 (1.9, 2.2) |
| Mean (95% CI) duration of antibiotics prescribed per patient, days a | 9.5 (8.1, 11.1) | 7.0 (4.1, 11.8) | 8.2 (6.2, 10.8)) | 6.5 (5.3, 7.8) | 8.7 (6.9, 10.7) | 7.9 (6.9, 10.5) | 10.6 (9.7, 11.5) | 7.2 (6.4, 8.0) | 16.1 (15.0, 17.1) | 14.6 (13.7, 15.5) | 8.6 (7.7, 9.5) | 10.9 (10.5, 11.3) |
| Patients prescribed ≥1 antibiotic, by class, n (%) a,b, c | ||||||||||||
| β-lactam agent | 15 (88.2) | 2 (100.0) | 4 (66.7) | 12 (70.6) | 8 (88.9) | 41 (80.4) | 32 (59.3) | 43 (95.6) | 51 (89.5) | 66 (98.5) | 37 (86.0) | 229 (86.1) |
| Lincosamide | 7 (41.2) | – | 3 (50.0) | – | – | 10 (19.6) | 39 (72.2) | 8 (17.8) | 35 (61.4) | 31 (46.3) | 4 (9.3) | 117 (44.0) |
| Aminoglycide | – | – | – | 1 (5.9) | – | 1 (2.0) | 5 (9.3) | 6 (13.3) | 5 (8.8) | 2 (3.0) | 3 (7.0) | 21 (7.9) |
| Glycopeptide | – | – | – | – | – | – | 3 (5.6) | – | 9 (15.8) | 5 (7.5) | 1 (2.3) | 18 (6.8) |
| Other | 7 (41.2) | – | 1 (16.7) | 5 (29.4) | 1 (11.1) | 14 (27.5) | 12 (22.2) | – | 2 (3.5) | 1 (1.5) | – | 15 (5.6) |
| Macrolide | – | – | – | 1 (5.9) | 1 (11.1) | 2 (3.9) | – | – | 2 (3.5) | – | 5 (11.6) | 7 (2.6) |
| Fluoroquinolone | – | – | – | – | – | – | – | 1 (2.2) | 2 (3.5) | – | 1 (2.3) | 4 (1.5) |
| Mean (95% CI) duration of use, by class, days a | ||||||||||||
| β-lactam agent | 5.8 (4.7, 7.1) | 7.0 (4.1, 11.8) | 4.3 (2.6, 6.8) | 6.2 (4.9, 7.7) | 7.1 (5.5, 9.2) | 6.0 (5.1, 7.0) | 8.4 (7.5, 9.5) | 6.2 (5.5,7.0) | 9.2 (8.4, 10.0) | 10.1 (9.3, 10.9) | 7.4 (6.5,8.3) | 8.1 (7.8, 8.5) |
| Lincosamide | 4.9 (3.5, 6.8) | – | 6.0 (3.8, 9.5) | – | 5.4 (4.1, 7.2) | 5.4 (4.7, 6.1) | 4.0 (2.8, 5.7) | 8.1 (7.2, 9.1) | 6.8 (5.9, 7.8) | 8.5 (6.1, 11.9) | 6.3 (5.7, 7.0) | |
| Aminoglycide | – | – | – | 1.0 (0.1, 7.1) | – | 1.0 (0.1, 7.1) | 4.2 (2.7, 6.4) | 3.5 (2.3, 5.4) | 5.4 (3.7, 7.8) | 8.5 (5.3, 13.7) | 5.7 (3.5, 9.1) | 5.2 (4.3, 6.3) |
| Glycopeptide | – | – | – | – | – | – | 6.0 (3.8, 9.5) | – | 9.0 (7.2, 11.2) | 14.8 (11.8, 18.6) | 5.0 (NA) | 8.0 (6.1, 10.3) |
| Other | 8.7 (5.9, 12.7) | – | 14.0 (8.3, 23.6) | 5.6 (3.9, 8.1) | 7.0 (3.3, 14.7) | 8.3 (6.4, 10.8) | 4.1 (3.1, 54) | – | 6.3 (4.0, 9.9) | 10.0(NA) | – | 6.4 (4.9, 8.4) |
| Macrolide | – | – | – | 7.0 (3.3, 14.7) | 14.0 (8.3, 23.7) | 9.9 (6.3, 15.6) | – | – | 4.5 (2.3, 8.6) | – | 6.6 (4.7, 9.3) | 5.4 (3.8, 7.9) |
| Fluoroquinolone | – | – | – | – | – | – | – | 3.0 (1.0, 9.3) | 9.0 (5.7, 14.3) | – | 7.0 (3.3, 14.7) | 5.7 (3.6, 9.2) |
CI Confidence Interval
a Among population of antibiotic users
b Reported for classes of antibiotics administered to > 1.0% of the total inpatient and/or outpatient population
c Patients may have been prescribed ≥1 antibiotic